Multidose Pump Systems
We offer various technologies with a full range of pump and valve platforms.
SP270+ and SP370+ SP27 and SP37 In-vitro Bioequivalence for nasal sprays Child Resistant solutionsEar Nose Throat (ENT)
Make every spray count
The number of drugs delivered through the ear, nose and throat is expanding.
We provide a comprehensive range of pumps, compatible with a wide choice of actuators for each delivery route (ear, nose and throat), suitable for regulated and low regulated markets.
We guarantee precision and dose consistency to maximize treatment efficacy and improve patients’ outcomes.
UniSpray
Unispray delivers one single-metered accurate dose, ideal for systemic delivery for emergency lifesaving and crisis treatment.
Discover More
Nasal Vaccine
Our nasal vaccine concept device is currently under development, ideally used for respiratory infections prevention such as covid-19, influenza amongst others.
Discover More
RetroNose®
RetroNose® is an innovative concept device for nasal drug delivery through oral administration. With RetroNose®, enhance therapeutic efficacy of your nasal drug with a better deposition.
Discover More
Electronic technologies
Thanks to our Electronic know-how and our capabilities to answer patients’ needs, we offer a full range of services for design, development and manufacturing of electronic devices for nasal delivery.
Safe'n'Spray Electronic Nasal deviceOur services
Integrated services from device selection to GMP manufacturing
We have developed end-to-end services and expertise in ENT device development, and device consulting, to complement our diverse portfolio of products to help you through every step of the journey.
Early-stage innovation
It is fundamental to integrate patients within the combination product development as early as possible.
We provide a full understanding of the patient journey and recommend user-related activities to further optimize patients’ experience for a specific drug/device combination product. Thanks to our extensive human factor capabilities, the pharma company could ensure that their selected device, in combination with their drug, is appropriate, safe and effective for the target population. Our support encompasses making a specific Instruction For Use (IFU) adapted to a certain target population, as well as supporting Human Factor activities in alignment with the pharma company’s chosen regulatory path.
Testing services for customer formulations
Thanks to our high-end laboratory facilities, we propose device plus formulation test services as well as test methods development for our customers’ needs. In the case of establishing in-vitro bioequivalence (IVBE), following regulatory guidance is extremely crucial. Thanks to our lab test capabilities, we can support specific generic projects through a complete set of tests that meets the authority’s prerequisite. This data generation will be statistically analyzed regarding USA and EU guidelines for eventual customers’ IVBE dossier registration filing.
FAQ
Intranasal delivery is a common route of administration for treating various indications, from allergic rhinitis to breakthrough cancer pain (fast-acting pain control by nasal spray).
Nasal delivery is an attractive option for locally acting medications (e.g. saline solutions, decongestants, corticosteroids or antihistamines) which treat allergic rhinitis and nasal congestion.
More drugs targeting other therapeutic fields and diseases may join the increasing ranks of marketed products for systemic delivery using the nasal route, which may vary from benign to serious health condition.
The nasal route is not invasive and does not require healthcare professionals’ intervention where patients can self-administer their remedy with a rapid onset.
Besides, it allows better bioavailability as drug administration via the nasal route avoids hepatic first-pass effect which could be encountered when taking medications orally.
Bioequivalence for nasal spray is a prerequisite for all generic applications.
Depending on the countries (in Europe) it can allow pharmaceutical companies to waive in-vivo clinical studies. For USA, the current expectation is to have in-vitro and in-vivo BE studies.
More about Nemera
Our services
End-to-end services and expertise in device development, device consulting, and contract manufacturing to complement our diverse portfolio of products and to help you through every step of the journey.
Discover moreKnowledge Hub
Cutting-edge insights, resources, press articles, and webinars to learn more about the holistic ecosystem of drug delivery device solutions.
Discover moreWho we are
We design and manufacture devices that maximize treatment efficacy and partner with our customers in their device strategies, to ultimately bring high-quality and safe treatment solutions to patients.
Discover more